Diagnostic solutions manufacturer Genomic Vision (GV) has signed a licensing agreement with Phyteneo to commercialise its HPV integration test in the Czech Republic.
The partnership between the two companies follows the success of a clinical study EXPL-HPV-002 carried out last month to identify cervical cancer.
The data procured from the study showed that the median value of HR-HPV virus integration in high-grade patients increases three-fold compared to patients with no lesion.
Phyteneo CEO Petr Behensky said: “We were very impressed by the first results of the EXPL-HPV-002 study and we believe that it will be a strong support to registration, and future launch of the product.
“The information provided by Genomic Vision test is completely new and gynaecologists are very excited by the idea of having the possibility to propose to their patients a new test that could help them to optimise their follow up and care.”
Under the terms of the agreement, Phyteneo will be responsible to register the test as a medical device from a regional regulatory agency State Institute for Drug Control, as well as its sales in the country.
After it is registered, Phyteneo will acquire a first molecular combing platform and it will be installed at an important clinical centre in the Czech Republic.
In future, the agreement may be expanded to include other Central Eastern European countries.
GV Corporate Development executive vice-president Stéphane Altaba said: “We were looking for a committed local partner with strong experience in registration and willing to launch the test in Czech Republic, where the HPV integration test was appreciated by the doctors and the patients.
“With Phyteneo and Petr Behensky, we have the right partner for making a success story in this pilot country.”
Every year, around 2.2 million screening procedures for cervical cancer are carried out in the Czech Republic. Nearly 180,000 women are detected with High risk-HPV.